EGFR mutation-positive non-small cell lung cancer
GPTKB entity
Statements (27)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:disease
|
| gptkbp:hasBiomarker |
gptkb:EGFR_mutation
|
| gptkbp:hasDiagnosticMethod |
EGFR mutation testing
|
| gptkbp:hasFirstLineTherapy |
gptkb:EGFR_tyrosine_kinase_inhibitor
|
| gptkbp:hasMolecularAlteration |
gptkb:EGFR_mutation
|
| gptkbp:hasPrimarySite |
gptkb:cancer
|
| gptkbp:hasResistanceMutation |
gptkb:EGFR_T790M_mutation
|
| gptkbp:hasTargetedTherapy |
gptkb:afatinib
gptkb:erlotinib gptkb:gefitinib gptkb:osimertinib gptkb:dacomitinib |
| https://www.w3.org/2000/01/rdf-schema#label |
EGFR mutation-positive non-small cell lung cancer
|
| gptkbp:ICD-10_code |
C34
|
| gptkbp:incidence |
more common in females
higher in East Asian populations higher in non-smokers |
| gptkbp:mutationAssociatedWith |
EGFR L858R mutation
EGFR exon 19 deletion |
| gptkbp:prognosis |
variable
|
| gptkbp:stageName |
gptkb:TNM_staging
|
| gptkbp:subclassOf |
gptkb:non-small_cell_lung_cancer
|
| gptkbp:treatment |
chemotherapy
tyrosine kinase inhibitors immunotherapy (less effective) |
| gptkbp:bfsParent |
gptkb:gefitinib
|
| gptkbp:bfsLayer |
7
|